Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD30 antibody-drug conjugate SGN-35T

An antibody-drug conjugate (ADC) composed of brentuximab (cAC10), a chimeric immunoglobuin G1 (IgG1) monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8) conjugated, via a protease-cleavable tripeptide linker, comprised of D-leucine-alanine-glutamate (DLAE), to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CD30 ADC SGN-35T targets, binds to and is internalized by CD30-positive tumor cells. Upon enzymatic cleavage of the cleavable linker, MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis of CD30-expressing tumor cells. In addition, SGN-35T induces bystander effect in neighboring tumor cells and immunogenic cell death (ICD). CD30 may be constitutively expressed in certain B- and T-cell lymphoma while expression is limited in normal, healthy cells. The linkage system in is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.
Synonym:ADC SGN-35T
anti-CD30 ADC SGN-35T
cAC10/MMAE antibody-drug conjugate SGN-35T
Code name:SGN 35T
SGN-35T
SGN35T
Search NCI's Drug Dictionary